RTN-CONTAINING THERAPEUTIC / PREVENTIVE AGENT AGAINST OSTEOPOROSIS, CHARACTERIZED THAT RTN IS ADDED ONCE ONCE A WEEK IN THE STANDARD DOSE OF 100-200 UNITS

摘要

1. An agent for treating or preventing osteoporosis that contains PTH as an active ingredient, characterized in that it is used together with a calcium-containing agent, and PTH is administered once a week in a standard dose of 100-200 units. An agent for treating or preventing osteoporosis according to claim 1, characterized in that the calcium-containing agent used in combination is administered once or several times a week. An agent for treating or preventing osteoporosis according to claim 1 or 2, characterized in that the calcium-containing agent used in combination is administered at a dose of 200-800 mg / day in the form of calcium. An agent for treating or preventing osteoporosis according to claim 1 or 2, wherein said PTH is human PTH (1-34) .5. An agent for treating or preventing osteoporosis according to claim 1 or 2 for administration over a period exceeding 24 weeks or 48 weeks. An agent for treating or preventing osteoporosis according to claim 1 or 2 for treating patients with osteoporosis who satisfy all of the following conditions 1-3 below: (1) Age 65 years or more, (2) Predominant bone fractures, (3) Bone density less than 80% of the average density of a young adult and / or a degree of bone atrophy I or higher. 7. An agent for treating or preventing osteoporosis according to claim 1 or 2 for treating or preventing secondary osteoporosis caused by a glucocorticoid or diabetic osteoporosis. An agent for treating or preventing osteoporosis according to claim 1 or 2 for treating or preventing osteoporosis in patients having at least one of the diseases (1) to (8) below as a complication: (1) Diabetes, (2) Hypertension, ( 3) Hyperlipidemia, (4) Arthralgia, (5) Osteoarthritis of the spine, (6)